MOLECULAR PARTNERS N/ CH0256379097 /
9/19/2024 5:31:35 PM | Chg. +0.0600 | Volume | Bid6:18:11 PM | Ask6:18:11 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
4.1000CHF | +1.49% | 10,521 Turnover: 42,627.9950 |
-Bid Size: 200 | 4.1000Ask Size: 1,853 | 149.05 mill.CHF | - | - |
GlobeNewswire
6/17
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
GlobeNewswire
6/14
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EH...
GlobeNewswire
6/11
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPi...
GlobeNewswire
6/1
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin)...
GlobeNewswire
5/16
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional...
GlobeNewswire
4/29
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supportin...
GlobeNewswire
4/17
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
GlobeNewswire
3/14
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
GlobeNewswire
3/1
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and ...
GlobeNewswire
1/7
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
1/5
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
GlobeNewswire
12/14/2023
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Co...
GlobeNewswire
12/10/2023
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/...
GlobeNewswire
11/14/2023
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summi...
GlobeNewswire
11/3/2023
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) ...
GlobeNewswire
11/2/2023
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with...
GlobeNewswire
11/1/2023
Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit
GlobeNewswire
10/26/2023
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin...